TP53 and ovarian carcinoma: Similarly, a study by Liu et al. showed that olaparib treatment was preferentially cytotoxic to TP53-mutant but not WT cell lines derived from muscle-invasive bladder cancer and NSCLC [27], and Wang et al. showed that low concentrations (5 μM) of olaparib induced cellular senescence through the p16/p53 pathway in both WT and mutant p53 ovarian cancer cells using senescence-associated β-galactosidase staining [53].